Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.

Alexander, Tobias

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. [electronic resource] - European journal of immunology 09 2018 - 1573-1579 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1521-4141

10.1002/eji.201847492 doi


Autoantibodies--blood
Bortezomib--therapeutic use
Complement System Proteins--metabolism
Humans
Immunoglobulins--blood
Lupus Erythematosus, Systemic--drug therapy
Lymphocyte Count
Plasma Cells--cytology
Precursor Cells, B-Lymphoid--cytology
Precursor Cells, T-Lymphoid--cytology
Proteasome Endopeptidase Complex--drug effects
Proteasome Inhibitors--therapeutic use